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1. Introduction
Hearing Loss (HL) is the most common sensory 
disorder, affecting 1 in every 500-1,000 newborns 
(http://hearing.screening.nhs.uk/nationalprog). It is 
estimated that 50-70% of HL is related to genetic causes. 
Almost two thirds of cases include non-syndromic 
forms (NSHL), since hearing impairment is the only 
sign. HL is divided into DFNB autosomal recessive 
(80%), DFNA autosomal dominant (17%), X-linked 
(2-3%) and mitochondrial type (> 1%) (1). Autosomal 
recessive NSHL (ARNSHL) is highly heterogeneous, 
with over 60 identified causative genes (http://
hereditaryhearingloss.org/). Remarkably, defects in one 
locus (DFNB1) accounts for up to 50% of the etiology 
in many western populations (2-4), which makes this the 
most common cause of NSHL (5). The DFNB1 locus 
containing GJB2 and GJB6 genes encode connexin26 
(Cx26) and connexin30 (Cx30) respectively. Connexins 
are a kind of gap junction protein involved in inner ear 
homeostasis via recycling of potassium ions (6). To 
date, more than 100 pathogenic mutations in the GJB2 
gene have been identified resulting in ARNSHL (7). The 
prevalence of GJB2 mutations varies among different 
populations (8-16). In Caucasians, c.35delG is the most 
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common mutation with carrier frequency as high as 
2-4% (17). However, c.235delC, c.167delT and c.71G>A 
are the most frequent mutations in the Japanese (18), 
Ashkenazi Jewish (19), and Indians (20), respectively. 
The Iran population is genetically heterogeneous and a 
mixture of several ethnicities; consanguineous pedigrees 
affected with ARNSHL have helped to identify many 
HL associated genes. Over the past 15 years, tremendous 
amounts of epidemiologic data have been collected on 
the Iranian population in order to determine the mutation 
spectrum and frequency of GJB2 mutations (21-30). It 
was shown that the mutation frequency of GJB2 varies 
between 0 and 35% among different regions of Iran and 
c.35delG is the most common mutation reported (31,32). 
In this paper, we summarized the published data on 
the frequency and profile of the GJB2 gene mutations 
in 812 unrelated families from 4 different provinces; 
namely Khorasan, Sistan & Baluchestan, Kerman and 
Hormozgan in east Iran compared to other parts of this 
country.
2. Methods and Analysis
2.1. Publication search
A systematic literature review of PubMed, Google 
Scholar, Web of Science, and Science Direct databases 
was conducted in English for articles published before 
April, 2019. The following keywords and medical 
subheadings were used simultaneously in each set: 
("hearing loss" or "deafness" or "hearing impairment") 
and ("GJB2") or ("connexine26") or ("35delG") and 
("Iran"). Alternative spellings were also considered. 
The literature search was performed by 2 independent 
researchers.
2.2. Inclusion criteria and data extraction, data 
analysis
Eligible studies included in our review met the 
following inclusion criteria: i) performed on non-
syndromic HL subjects, ii) described ethnicity of tested 
subjects, and iii) detected all GJB2 mutations. Studies 
were excluded if HL was a result of environmental 
factors such as infection, trauma, rubella, meningitis, 
mumps, ototoxic drugs and premature birth. The flow 
diagram of the selected eligible studies is shown in 
Figure 1. The necessary data were extracted from the 
final eligible articles as follows: first author, publication 
year, subject ethnicity and number of cases. The 
frequency and mutation type of GJB2 were extracted 
from relevant studies and categorized, corresponding 
with geographical boundaries. In silico analyses were 
also performed with available software tools to predict 
pathogenicity of the mutations.
3. Results
A total of 6 studies comprising 812 unrelated families 
from 4 provinces were included for analysis. The 
173
Figure 1. Flow chart of review process.
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a GJB2 mutation frequency of 13.7% for Khorasan 
province and 6.3% for Sistan & Baluchestan province. 
In 2007, Hashemzadeh et al. stated that the frequency 
of GJB2-related HL is in 14.6% of deaf families (130 of 
890 families). They also found the highest percentage of 
GJB2 related HL in the north and northwest regions of 
Iran (27%), while it was less than 4% in the Southeast 
region (36). The findings of our study shows that the 
contribution of GJB2 mutations to ARNSHL is 13.7% 
in Khorasan province, which is similar to the presented 
data from Semnan province (37). Bazazzadegan et al. 
screened 111 ARNSHL families from Semnan province 
in center Iran for GJB2 mutations. They reported 
that GJB2 mutations were detected in 11.5% of the 
ARNSHL families studied. 
 Another finding of this study was the mutation 
spectrum of southeast Iran, which was different from 
those of other Iranian population regions. Two hundred 
and ninety two unrelated Baluchi deaf families were 
reviewed, with a frequency of 6.2% for GJB2 gene 
mutations. Interestingly, c.71G>A was the most frequent 
GJB2 mutation, while c.35delG was absent in this 
ethnicity. Results obtained for the carrier frequency of 
c.71G>A mutation was 70% in the Baluchi population 
whereas 4.2% in the rest of eastern provinces. 
However, the Baluchi population is ethnically distinct 
from the rest of Iran. Besides, 121 unrelated ARNSHL 
families from Hormozgan province were reviewed, 
with a frequency of 8.4% for GJB2 gene mutations. 
This rate of GJB2 mutation has been reported in some 
populations of the south of Iran like Khuzestan province 
(37). In the study performed by Bazazzadegan et al. (37) 
on 103 ARNSHL families indicated that GJB2 related 
HL accounted for 7% in Kerman province. This is 
about one third of the frequency of the GJB2 mutations 
in Isfahan province. In the previous study, we showed 
that GJB2 mutations explain the cause of ARNSHL in 
22.5% of patients from Isfahan province in the center of 
Iran (38). In addition, Davarnia et al. (39) screened 50 
NSHL families from Ardebil province in northwest Iran 
for GJB2 mutations. They reported that GJB2 mutations 
were found in 26% of the NSHL families studied. On 
the basis of these results, it can be concluded that the 
frequency of GJB2 mutations decreases gradually both 
west to east and north to south (Figure 3), drawing the 
migration pathway of the initial founders.
 In our studied populations, the most common 
mutation was c.35delG, accounting for 48.5% of GJB2 
mutations. The c.35delG mutation (deletion of guanine 
in position 30-35; rs80338939) is the most common 
groups studied consisted of 296 families from Khorasan 
province (36.45%), 292 families from Sistan & 
Baluchestan (35.9%), 121 families from Hormozgan 
(14.9%) and 103 families from Kerman province 
(12.6%). Among these families, 78.7% reported parental 
consanguinity while in 21.3% close consanguinity was 
denied (Table 1). The GJB2 mutation allele frequencies 
of each studied group included 13.7%, 8.4%, 7%, 
6.3% of total studied families (n = 812) of Khorasan, 
Hormozgan, Kerman, and Sistan & Baluchestan 
provinces, respectively. A total of 19 different 
variants were identified, 14 of which were reported 
as pathogenic. These include: c.-23+1G>A, c.35delG, 
c.71G>A, c. 336G>T, c.167delT, c.235delC, c.29delT, 
c.358-360delGAG, c.238G>A, c.427C>T, c.269T>C, 
c.511G>A, c.229T>C, c.465T>A. The GJB2 mutation 
spectrum and frequency revealed in this review is listed 
in Table 2. In the studied populations, c.35delG was 
the most frequent mutation accounting for 48.5% of 
the populations studied. The highest rate of c.35delG 
mutation was detected in Khorasan province with an 
allele frequency of 10.1% while we did not find any 
c.35delG mutations in Sistan & Baluchestan (Figure 
2). A specific combination of GJB2 mutation types and 
frequencies were found in different studied provinces 
(Table 2). A higher GJB2 mutation diversity (9 types) 
was observed in Khorasan province while the lowest 
diversity was identified in Sistan & Baluchestan (4 
types). 
4. Discussion
The identification of genes causing non-syndromic 
hearing Loss (NSHL) has partially resolved the puzzle 
of clinical and genetic heterogeneity of HL (33-35). 
Among these genes the gene with the most significant 
impact on population genetics and genetic counselling is 
the GJB2 gene with the mutation c.35delG that accounts 
for the majority of mutations in deaf Caucasians (12). 
Studies published so far have reported the differences in 
frequency of the mutation in different populations, even 
from neighboring countries. The Iranian population is 
composed of many different ethnic groups. According 
to this fact, it is necessary to discuss ethnic specific 
data. This study reviews the prevalence and type of 
the GJB2 gene mutations of 812 deaf families from 
four different provinces of this country. Here, the most 
consistent finding was the reduction of GJB2 mutation 
frequencies of north to south Iran. Our data showed a 
north to south gradient among Iranian populations with 
Table 1. The frequency of consanguinity in different provinces of east Iran
Province
Consanguinity
Non-consanguinity
Total
Sistan & Baluch
258
  46
292
Kerman
  87
  16
103
Khorasan
212
  84
296
Hormozgan
  75
  46
121
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mutation in many world populations as well as many 
countries in the Middle East such as Turkey, north and 
northwest of Iran (40). The study of the geographical 
distribution of the GJB2 mutations showed less allelic 
heterogeneity in the east compared to the north of 
Iran. The four most frequent mutations of the GJB2 
gene in the west of Iran, namely, c.35delG, c.71G>A, 
c.358_360delGAG and c.167delT are responsible for 
~79.8% of all pathogenic alleles in east Iran (Table 2). 
The c.35delG mutation, which is the most common 
(up to 85%) among northern regions (41), makes up 
48.5% of GJB2 mutations in the eastern populations. 
The c.71G>A, c.358_360delGAG and c.167delT are 
the second, third and fourth most common mutations, 
with a sum of 20.9%, 5.2% and 5.2% of all pathogenic 
alleles. The p.Trp24*, a nonsense mutation is the result 
of c.71G > A transition, changing the TGG codon for 
Trp residue to a stop codon, which leads to a truncated 
protein with probably no functional properties. In silico 
analyses are consistent with the pathogenicity of the 
mutation (Table 1). Sistan & Baluchestan province 
is located on the western border of Pakistan and is 
populated mainly by Sistani & Baluchi ethnicities. The 
c.71G > A mutation is the most common mutation in 
Pakistan and Indian populations. The rate of carriers of 
c.71G > A mutation is 4.08% in the Pakistan population 
(42,43). This mutation shows a high frequency in 
the Baluchi group, where the population is related to 
neighboring Pakistan. This review showed a particular 
combination of GJB2 mutations diversity in different 
provinces of east Iran. A higher GJB2 mutations 
diversity (9 types) was detected in Khorasan province, 
suggesting the co-existence of several different 
ethnic groups and immigrations to big cities such as 
Mashhad during the last century. In addition, historical 
background like occurrence of different wars with 
foreign nations, immigration, and location of the route 
of the Silk Road could support this diversity. In contrast 
with the high diversity of Khorasan province, we found 
a very low rate of diversity in some populations such 
as the Baluchi population who are probably isolated 
with cultural and geographical barriers. The limitation 
of this study is a small number of studies especially 
for Kerman province (103 families). Therefore, 
more screening programs in the east population are, 
warranted.
5. Conclusion
The critical and specific position of Iran and the 
existence of various ethnic groups with different 
cultures suggest high heterogeneity throughout Iran 
but specific intra ethnic traditions such as intragroup 
marriages may give rise to a high homogeneity in some 
loci and mutations within groups. Our study revealed 
a frequency of 8.8% for GJB2 mutations, relatively 
low compared to other studies of central populations 
with estimated frequencies between 13-15%. Referring 
to the GJB2 mutations, one section of this cohort 
had the c.35delG mutation, so this mutation is the 
most common mutation that is tested first. In studied 
populations, specific mutations are common, which are 
detected in each group; for example, the frequency of 
the c.71G>A shows a high rate in Sistan & Baluchestan 
province, accounting for 70% of the mutant alleles. In 
addition, the causes of HL in some populations such as 
Baluchi are likely more homogenous than other parts 
of east Iran. This review highlights the importance 
of GJB2 mutations in development of HL in eastern 
parts of Iran and are of great importance for successful 
disease management and interventions, mainly for 
genetic counseling and cochlear implants
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Figure 2. The allele frequency of c.35del G mutation in 
different provinces of east Iran.
Figure 3. The prevalence of GJB2-related mutations in 
different regions of Iran (west 22-25%, north 27-38% 
(32,41), center 13-15% (32,37)). Four eastern provinces (Sistan 
& Baluchestan, Hormozgan, Kerman and Khorasan) are shown 
in the map.
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